Navigation Links
NexBio to Present at 2007 BIOCOM Investor Conference

SAN DIEGO, Oct. 31 /PRNewswire/ -- NexBio, Inc. a privately held development-stage biopharmaceutical company located in San Diego, announced today that Dr. David Wurtman, its Vice President of Corporate Development, will present a corporate overview and update at the BIOCOM Investor Conference on November 1, 2007.

NexBio's mission is to save lives, and to improve the quality of life, by creating and commercializing novel, broad-spectrum biopharmaceuticals to prevent and treat current and emerging life-threatening human viral respiratory diseases. NexBio has received significant financial support through grants and contracts from the National Institutes of Health for development of Fludase(TM), its lead program, a first-in-class broad-spectrum prophylactic and therapeutic agent to potentially address all annual and pandemic variations of influenza, including the Avian IFV H5N1 ("Bird Flu"), as well as parainfluenza. Product candidates in NexBio's pipeline may address additional viral infections, such as RSV.

The company also possesses TOSAP(TM), a novel, elegant, flexible & scalable formulation technology, invented by NexBio scientists, which it uses to make dry-powder microspheres to allow drugs to be delivered by inhalation. TOSAP(TM) is being applied to expand the company's pipeline, and is also being licensed to partners who wish to formulate their own compounds.

NexBio is actively seeking corporate partnerships from companies that have extensive experience in late stage drug development and commercialization, as well as entertaining inquiries from financing sources that may wish to invest in the company.

For more information about NexBio, Inc., please visit


David Wurtman, M.D., M.B.A

VP, Corporate Development

10665 Sorrento Valley Road

San Diego, CA 92121

Phone: (858) 452-2631

Note: FDA has yet to approve the name Fludase.

SOURCE NexBio, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... 2015 , ... December 1, 2015 -- InstantLabs is adding ... product line of food safety and seafood fraud prevention tools. , The new ... InstantLabs to offer fast, reliable species identification for the four most popular salmon. ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
(Date:12/1/2015)... , Dec. 1, 2015 Breg, Inc ... services, announced today that it has been awarded three ... Members served by Novation will have access to improved ... bracing products and soft goods dedicated to advancing orthopedic ... The aging U.S. population, rising prevalence of chronic ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
Breaking Medicine Technology: